Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts

Key Points

• Consensus "Hold": Six analysts rate Invivyd a consensus Hold (1 sell, 2 hold, 3 buy) with an average 12‑month target price of $8.00.
• Insider selling: Insiders sold 227,172 shares worth $354,534 over the past 90 days — including February sales by Jill Andersen and Julie Green — and insiders currently own about 25.40% of the stock.
• Share performance: The stock opened at about $1.19 (down 13.1%), trading within a 12‑month range of $0.46–$3.07 and carrying a market capitalization near $336 million.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) has received an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.00.

Several research firms recently commented on IVVD. BTIG Research reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Invivyd in a research report on Thursday, February 26th. Weiss Ratings reissued a "sell (e+)" rating on shares of Invivyd in a research note on Monday, December 29th.

Insider Buying and Selling at Invivyd

In other Invivyd news, insider Jill Andersen sold 34,939 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $55,203.62. Following the sale, the insider owned 181,736 shares in the company, valued at approximately $287,142.88. The trade was a 16.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Julie Green sold 20,964 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $33,123.12. Following the transaction, the insider directly owned 107,717 shares of the company's stock, valued at approximately $170,192.86. This trade represents a 16.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 227,172 shares of company stock valued at $354,534 in the last 90 days. 25.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Invivyd

Hedge funds and other institutional investors have recently made changes to their positions in the business. Courier Capital LLC bought a new stake in Invivyd during the 4th quarter worth about $25,000. Bronte Capital Management Pty Ltd. bought a new position in shares of Invivyd in the 4th quarter valued at about $27,000. DRW Securities LLC bought a new position in shares of Invivyd in the 4th quarter valued at about $27,000. ProShare Advisors LLC acquired a new stake in shares of Invivyd in the fourth quarter valued at about $30,000. Finally, State of Wyoming acquired a new stake in shares of Invivyd in the fourth quarter valued at about $30,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Stock Down 13.1%

Invivyd stock opened at $1.19 on Tuesday. The company has a 50 day moving average of $1.70 and a 200-day moving average of $1.91. Invivyd has a twelve month low of $0.46 and a twelve month high of $3.07. The stock has a market capitalization of $336.29 million, a PE ratio of -3.72 and a beta of 0.61.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.